Literature DB >> 23169328

Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults.

Caryn G Morse1, Lori E Dodd, Khanh Nghiem, Rene Costello, Gyorgy Csako, H Clifford Lane, Jay N Lozier, Joseph A Kovacs.   

Abstract

BACKGROUND: A high incidence of nontraumatic osteonecrosis has been reported in HIV-infected patients. We investigated the levels of D-dimer and C-reactive protein (CRP) in a cohort of HIV-infected adults with and without osteonecrosis of the femoral head.
METHODS: Forty-three HIV-infected patients with osteonecrosis of the femoral head and a comparison group of 50 HIV-infected patients with negative MRI of the hips and for whom serial plasma samples were available were included. D-dimer and CRP levels were measured prior to and at the time of diagnosis for osteonecrosis patients, at the time of negative MRI of the hips for controls, and at least 6 months later for both groups.
RESULTS: Biomarker levels were elevated at the time of diagnosis in the osteonecrosis cohort compared with controls. Median D-dimer value was 0.32 μg/ml in the osteonecrosis group compared with less than 0.22 μg/ml in the control group (P = 0.016). For CRP, the corresponding values were 2.52 mg/l and 1.23 mg/l (P = 0.003). Postdiagnosis, D-dimer and CRP levels were also elevated in the osteonecrosis patients compared with controls. Linear regression demonstrated a rise in D-dimer levels from prediagnosis to diagnosis in the osteonecrosis patients whereas CRP levels did not change significantly over time.
CONCLUSION: Compared to controls, patients who developed osteonecrosis had elevated levels of D-dimer and CRP at diagnosis. D-dimer levels increased whereas CRP levels did not change significantly from prediagnosis to diagnosis. These data suggest that patients with higher levels of inflammation are at an increased risk of osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23169328      PMCID: PMC5507350          DOI: 10.1097/QAD.0b013e32835c206a

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.

Authors:  I M NILSSON; H KROOK; N H STERNBY; E SODERBERG; N SODERSTROM
Journal:  Acta Med Scand       Date:  1961-03

2.  Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study.

Authors:  Barbara Hasse; Bruno Ledergerber; Matthias Egger; Markus Flepp; Stefano Bachmann; Enos Bernasconi; Martin Egger; Sophie Guyot; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

3.  Procoagulants and osteonecrosis.

Authors:  Lynne C Jones; Michael A Mont; Tung B Le; Michelle Petri; David S Hungerford; Ping Wang; Charles J Glueck
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

4.  C-reactive protein is a marker for human immunodeficiency virus disease progression.

Authors:  Bryan Lau; A Richey Sharrett; Larry A Kingsley; Wendy Post; Frank J Palella; Barbara Visscher; Stephen J Gange
Journal:  Arch Intern Med       Date:  2006-01-09

5.  Hypofibrinolysis, thrombophilia, osteonecrosis.

Authors:  C J Glueck; R A Freiberg; R N Fontaine; T Tracy; P Wang
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

6.  C-reactive protein is an independent predictor of mortality in women with HIV-1 infection.

Authors:  Joseph G Feldman; Philip Goldwasser; Susan Holman; Jack DeHovitz; Howard Minkoff
Journal:  J Acquir Immune Defic Syndr       Date:  2003-02-01       Impact factor: 3.731

7.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

8.  Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.

Authors:  Brian O Porter; Jean Shen; Joseph A Kovacs; Richard T Davey; Catherine Rehm; Jay Lozier; Gyorgy Csako; Khanh Nghiem; Rene Costello; Henry Clifford Lane; Irini Sereti
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

9.  Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.

Authors:  Michael S Boger; Ayumi Shintani; Leigh Anne Redhage; Valerie Mitchell; David W Haas; Jason D Morrow; Todd Hulgan
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  Idiopathic and secondary osteonecrosis of the femoral head show different thrombophilic changes and normal or higher levels of platelet growth factors.

Authors:  Elisabetta Cenni; Caterina Fotia; Enis Rustemi; Kimitachi Yuasa; Giuseppe Caltavuturo; Armando Giunti; Nicola Baldini
Journal:  Acta Orthop       Date:  2011-02-01       Impact factor: 3.717

View more
  8 in total

Review 1.  Immune activation and HIV persistence: considerations for novel therapeutic interventions.

Authors:  Hiroyu Hatano
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

2.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Authors:  Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-08-23       Impact factor: 5.226

3.  Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications.

Authors:  David Shasha; Bruce D Walker
Journal:  Front Immunol       Date:  2013-06-25       Impact factor: 7.561

4.  Cirrhosis is a risk factor for total hip arthroplasty for avascular necrosis.

Authors:  Thomas Deleuran; Søren Overgaard; Hendrik Vilstrup; Peter Jepsen
Journal:  Acta Orthop       Date:  2016-02-22       Impact factor: 3.717

Review 5.  Bone Diseases in Patients with Chronic Liver Disease.

Authors:  Hae Min Jeong; Dong Joon Kim
Journal:  Int J Mol Sci       Date:  2019-08-31       Impact factor: 5.923

6.  Urinary miRNAs as biomarkers for idiopathic osteonecrosis of femoral head: A multicentre study.

Authors:  Yongheng Ye; Yue Peng; Peiheng He; Qinqin Zhang; Dongliang Xu
Journal:  J Orthop Translat       Date:  2020-02-21       Impact factor: 5.191

7.  Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.

Authors:  Kalilou Diallo; Bruce Shinga Wembulua; Mohamadou Aidara; Armel Alleyo; Noel Magloire Manga
Journal:  J Med Case Rep       Date:  2021-12-18

8.  Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.

Authors:  Hiroyu Hatano; Steven A Yukl; April L Ferre; Erin H Graf; Ma Somsouk; Elizabeth Sinclair; Mohamed Abdel-Mohsen; Teri Liegler; Kara Harvill; Rebecca Hoh; Sarah Palmer; Peter Bacchetti; Peter W Hunt; Jeffrey N Martin; Joseph M McCune; Russell P Tracy; Michael P Busch; Una O'Doherty; Barbara L Shacklett; Joseph K Wong; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.